文献速递炎症性肠病

早期联合免疫抑制可减少长病程克罗恩病并发症:REACT事后分析

Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT.
PubMed 文献 · Clin Gastroenterol Hepatol · 2020-12-18

该研究为REACT试验的事后分析,评估基线病程对早期联合免疫抑制(ECI)与传统管理(CM)在手术、住院或克罗恩病相关并发症方面的影响。REACT试验显示,ECI联合症状导向的治疗升级24个月可降低手术、住院或CD相关并发症风险。本分析旨在探讨基线病程是否影响ECI与CM的上述结局差异。

要点

  • REACT试验事后分析,评估基线病程对ECI与CM结局的影响。
  • ECI联合症状导向治疗升级24个月可降低手术、住院或CD相关并发症风险。
  • 病程早期治疗可能与较低并发症风险相关,但数据有限。

核心结论

  • ECI联合症状导向治疗升级24个月可降低手术、住院或CD相关并发症风险。
  • 基线病程对ECI与CM结局差异的影响尚需进一步分析。

研究设计与样本

  • REACT试验的事后分析。
  • REACT试验为随机对照试验,比较ECI与CM,治疗升级基于症状,持续24个月。

主要发现

  • ECI组相比CM组,手术、住院或CD相关并发症风险更低。
  • 病程早期治疗可能与降低并发症风险相关,但数据有限。

临床怎么用

  • 对于长病程克罗恩病患者,早期联合免疫抑制可能减少并发症。
  • 需结合基线病程评估ECI的获益。

局限性

  • 为事后分析,可能存在偏倚。
  • 基线病程对结局影响的数据有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Crohn's disease (CD) can lead to bowel damage, stricturing, and obstruction thereby resulting in surgery and hospitalization. The Randomized Evaluation of an Algorithm for Crohn's Treatment (REACT) trial showed that early combined immunosuppression (ECI) with symptom-based treatment escalation for 24 months resulted in a lower risk of surgery, hospitalization, or CD-related complications compared with conventional management (CM).1 Treatment earlier in the disease course may be associated with reduced risk of complications compared with later initiation, although data are sparse.2 We performed a post hoc analysis of REACT to evaluate the impact of baseline disease duration on surgery, hospitalization, or CD-related complications in patients treated with ECI compared with CM.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Hanzel J, Ma C, Zou G, et al. Early Combined Immunosuppression Reduces Complications in Long-standing Crohn's Disease: A Post Hoc Analysis of REACT. Clin Gastroenterol Hepatol. 2020. PMID: 33346141. doi:10.1016/j.cgh.2020.12.019

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。